News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Redx Pharma achieves milestone with dosing of first participant in Phase 1 clinical trial for RXC008

Redx Pharma PLC

Redx Pharma PLC (AIM:REDX) CEO Lisa Anson discusses the enrollment of the first participant in its RXC008 Phase 1 clinical trial in an interview with Proactive's Stephen Gunnion. RXC008 is a 'first-in-class' ROCK inhibitor, designed to be gut-restricted, targeting fibrostenotic Crohn's disease. This oral molecule inhibits ROCK1 and ROCK2, aiming to avoid systemic side effects like hypertension, and providing targeted action in the gut. This development marks a significant step from laboratory to patient-focused clinical development. Anson highlighted the unmet need for Crohn's disease treatment, particularly for patients with fibrostenotic complications, where currently no drug treatments are available, leaving surgery as the only option. The next steps for the RXC008 programme include escalating doses in healthy volunteers, with plans to move into patient trials towards the end of the year. Additionally, Anson mentioned Redx Pharma's broader portfolio, noting that RXC008 is the sixth molecule from Redx to enter clinical trials, showcasing the company's drug discovery prowess. Other key developments include the Phase 2 trials of RXC007 for lung fibrosis and RXC004 for cancer, both expected to report data this year. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 08, 2024 05:46 AM Eastern Standard Time

Video
Article thumbnail News Release

Roughly Half of Nations That Invest in AI Develop Their Own Generative Models, Reveals the First Global GenAI Landscape

AIport

AIport, an online community dedicated to covering the latest international ML developments, has crafted the first volume of its Global Generative AI Landscape 2024. This initial edition examines notable GenAI players worldwide across several key categories. This is the first generative AI landscape analysis to emphasize regional attributes and encompass four times more nations than the average GenAI landscape available to the public. The research process involved examining all 62 countries invested in the AI market, as featured in the Global AI Index by Tortoise. In-house model developers were identified, filtered by the team of editors and data scientists, and subsequently cross-referenced with current GenAI landscapes from Sequoia Capital, Antler, Base10, and others, before being segmented into ten GenAI categories. As the final step, the data was divided into continental regions: North America, South America, Europe, Asia, Oceania, and Africa. The first volume of the global GenAI landscape from AIport aims to present a balanced view of international companies, encompassing not only Western firms, but also those from other regions. The landscape offers a comprehensive analysis, detailing which players are developing GenAI solutions, their locations, and the specific nature of their contributions. It contains a total of 128 generative models from 107 companies. As Avi Chawla, a data scientist and community manager at AIport, put it: “We noticed that many generative AI landscapes tend to focus either on the Silicon Valley giants or the tech powerhouses of Europe, covering no more than 10 countries on average. While this approach does serve its purpose, it can’t really offer a complete picture. To address this, we decided to dig deeper, and this is what we came up with after weeks of research. We believe Volume 1 of our Global Generative AI Landscape 2024 provides an objectively international outlook. And we’re also planning to delve into other aspects of GenAI more closely in the future.” The landscape and key highlights Of the 62 countries listed in the Global AI Index, only 35 develop their GenAI solutions in-house. Roughly 90% of them focus on one model type. Regional leaders by the number of active GenAI companies are North America – USA; South America – Argentina; Europe – UK and France; Asia – China and Israel; Oceania – Australia and New Zealand; Africa – South Africa. The average number of GenAI models per company is the highest in North America, being the only region to have at least one model from each of the 10 model categories. Approximately 10% of all companies covered in the study have implemented multimodality in their GenAI models, with a majority of these developers located in the US. This indicates that while multimodality represents an emerging trend, its adoption outside North America still remains in the nascent stages. A total of 11 companies worldwide have developed more than one type of GenAI model. Stability AI leads with five distinct GenAI model types (image, video, audio, 3D, and code), followed closely by OpenAI (chatbot, audio, video, and multimodal) and Google (text, image, audio, and multimodal) – both with four model types. Microsoft, Meta, Tencent, Baidu, and Yandex are among those companies that developed between two to three types of distinct GenAI models. 13 companies have developed multiple models within a single GenAI category. AssemblyAI has two speech-to-text models, MosaicML offers two iterations of its MPT for code generation, while IPOXCap has introduced two chatbots designed for business intelligence applications. About AIport AIport is an online community of AI writers, researchers, and data scientists that aims to provide a transnational perspective on AI. Recognizing that most ML-related publications primarily focus on the “big leagues” in the West, AIport seeks to be more inclusive by widening the angle and broadening the narrative. This approach ensures a more diverse and impartial representation, offering a well-rounded take to the global AI community. Contact Details NettResults LLC Nick Leighton +1 949-478-5880 nick.leighton@nettresultsllc.com Company Website https://aiport.substack.com/

March 07, 2024 10:22 AM Pacific Standard Time

Article thumbnail News Release

Innoveren Scientific's (OTCMKTS: IVRN) 510(k) Submission Sparks A New Hope For Patients Living With Chronic Non-Healing Wounds

Benzinga

By Jeremy Golden, Benzinga IVRN has completed a 510(k) submission for its SkinDisc TM Lite and SkinDisc TM regenerative medicine technology. The company says that what differentiates this technology from other regenerative products is the fact that it only requires one application to achieve healing in four to nine weeks and comes packaged as a disposable kit. An aging U.S. population with increasingly complex medical diagnoses has doctors and clinicians under pressure to diagnose and treat patients while restoring their quality of life. With the goal of doing just that, a life science and biotech incubator company is advancing a wound-healing product. Focused on advancing new technologies in areas of unmet need across multiple indications, Innoveren Scientific Inc. This is a significant advancement when compared to current treatment approaches that require weekly applications and can take 12-20 weeks to heal. Generally, people have to apply treatment products every three days before they see any impact. With SkinDisc, only one application is needed. SkinDisc TM was acquired by Innoveren Scientific in December of 2022. A breakthrough stem cell therapy technology, SkinDisc TM has positioned the company to combat the rising prevalence of acute, chronic and surgical wounds with an effective and affordable treatment. As outlined in its submission, SkinDisc TM combines stem cells from the patient and several other molecular components to stimulate tissue regeneration, which results in rapid growth of the host tissue. To best serve those who can benefit from this proprietary technology, Innoveren Scientific plans to work with surgeons, podiatrists and physicians to treat patients with severe trauma-based wounds and non-healing chronic wounds, which affected nearly 16.3% of Medicare beneficiaries in 2019, according to a recent study by the University of Pittsburgh Medical Center. Those numbers are only expected to continue on an upward trajectory. Innoveren's recent submission to the U.S. Food & Drug Administration (FDA) is primarily focused on chronic non-healing wounds and burns, an area of medicine where current treatment options have stagnated. With patented or under-patented components, SkinDisc TM has treated over 500 patients to date. Innoveren reports that early clinical outcomes of those who used SkinDisc TM demonstrated significant results relative to current treatment options in wound healing and limb salvage. Innoveren Scientific expects to receive a response from the FDA by mid-May 2024 for both SkinDisc TM and SkinDisc TM Lite. This 510(k) submission is one of three the company has in its pipeline utilizing the body's own cells to achieve successful recovery of the patient. In the coming months, Innoveren plans to submit an application to the FDA for its SkinDisc TM Ultra technology, an iteration that incorporates Bone Marrow Aspirate (BMA) and would only be available for use in operating rooms and limb salvage procedures; specifically in cases of severe trauma, infections or diabetic foot ulcers. In addition to SkinDisc TM, the company also has BreatheEasy, a 510(k) De Novo pathway medical device that helps patients struggling with chronic obstructive pulmonary disease (COPD), as well as other closely related diseases such as chronic bronchitis and emphysema. Featured photo by megaflopp on Shutterstock. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

March 07, 2024 08:30 AM Eastern Standard Time

Image
Article thumbnail News Release

How Healthcare Triangle (NASDAQ: HCTI) Is Helping Drive AI Adoption In Healthcare

Benzinga

By Faith Ashmore, Benzinga AI is rapidly transforming the healthcare industry, with an increasing demand and need for its implementation. One of the key drivers behind this rising demand is the ability of AI algorithms to analyze large volumes of patient data, quickly identifying patterns and making accurate predictions about diseases, treatment plans and outcomes. The implementation of AI in healthcare has the potential to revolutionize the industry, improving patient outcomes, reducing costs, and ultimately, saving lives. Healthcare is at a pivot point where AI-driven solutions are becoming more and more common. Companies that were quick to adapt or are currently taking steps to integrate AI are likely to be much further ahead than companies that are resistant to the technology. However, not every healthcare company has the capacity to seamlessly integrate AI technology into its systems. That's where organizations like Healthcare Triangle Inc. (NASDAQ: HCTI) come into play. Healthcare Triangle works collaboratively with various healthcare entities, such as hospitals, health systems, payers and pharma/life sciences organizations. The company focuses on developing specific AI applications that address clinical needs across a wide range of medical specialties. Whether it's using predictive analytics in oncology or precision medicine in cardiology, its goal is to revolutionize patient care in every aspect. This tailored approach represents a shift towards a healthcare ecosystem where AI-driven insights play an integral role in clinical decision-making, ensuring that healthcare providers remain at the forefront of an ever-evolving industry. “As we navigate towards a future where AI integration becomes synonymous with healthcare excellence, our solutions and services will represent a crucial pivot point,” shared Anand Kumar, Chief Revenue Officer at Healthcare Triangle. “We are setting a new standard for patient care, leveraging AI and LLMs to deliver personalized, predictive, and effective healthcare solutions with our expertise in providing privacy and security adhering to our HITRUST certification and HIPAA compliance. The future is unequivocal in its demand for AI enablement, and with Healthcare Triangle, healthcare providers are equipped to meet this challenge head-on.” The market for AI in healthcare is forecasted to experience growth; in 2023, the global AI in healthcare market was valued at $22.45 billion and it is projected to reach $53.0 billion by 2024. This upward trend reflects the market's progression from $11.06 billion in 2021 to approximately $15.1 billion by the end of 2022. What's particularly noteworthy is the projected overall market value of $187.95 billion by 2030. AI has the potential to revolutionize healthcare among other sectors, and companies like Healthcare Triangle are helping shape the future. Featured photo by Steve Johnson on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

March 07, 2024 08:25 AM Eastern Standard Time

Image
Article thumbnail News Release

Forum Health Tackles Chronic Illness Head On with Expansion of Two Clinics in the Midwest

Forum Health

Forum Health, LLC, nationwide network of integrative and functional medicine providers, reinforces its commitment to combating chronic illness with the addition of Golden Rey Integrative Medical Center led by Kristen H. Reynolds, MD, Founder and Medical Director. With two thriving locations in Wisconsin, the practice currently focuses on functional medicine with an expertise in chronic, complex conditions, including Lyme disease; and unique and effective treatments such as hyperbaric oxygen therapy and medical ozone therapies. Learn more about Golden Rey Integrative Medical Center here. Chronic illness is more prevalent than ever, and Lyme disease continues to be a leading culprit with approximately 476,000 people contracting Lyme disease each year in the United States. In 2022, Wisconsin alone had 5,327 cases of Lyme disease - more than doubled in the past 15 years with actual numbers likely to be much higher. Phil Hagerman, Forum Health CEO: “A significant portion of our patients come to Forum Health with some underlying chronic issue that traditional medicine has failed to identify, much less treat. Our expansion into this market is to fill an obvious and continued need.” Dr. Reynolds is triple-trained: board-certified in family medicine, fellowship-trained and board-certified in integrative medicine, and certified in functional medicine by the Institute for Functional Medicine. She has additional training in hyperbarics and medical ozone therapies. Kristen H. Reynolds, MD, Founder and Medical Director: “Healing from complex conditions began as a personal journey with my children and quickly grew into dedicating my practice to helping others heal using treatments not otherwise available in a conventional healthcare model. Forum Health will give us the platform and technology to grow and provide access to these services for even more people.” Golden Rey Integrative Medical Center offers a variety of treatments tailored to patients suffering from chronic symptoms including: IV Therapies Hyperbaric Oxygen Therapy Pulsed Electromagnetic Frequency (PEMF) Prolozone Medical Ozone Therapies Nutrition and Health Coaching Supplements Learn more about joining the Forum Health network here. About Forum Health, LLC Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com. Contact Details Forum Health, LLC Britt Wittelsberger +1 410-852-0738 bwittelsberger@forumhealth.com Company Website https://forumhealth.com

March 06, 2024 08:50 AM Eastern Standard Time

Image
Article thumbnail News Release

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Benzinga

By Faith Ashmore, Benzinga In the world of medicine, sometimes the most unexpected biological material can become vital to treatments for deadly diseases. One example of this is adenoviruses, which are non-enveloped, double-stranded DNA viruses that belong to the Adenoviridae family. They have a wide range of serotypes, or strains, with more than 50 types known to infect humans. Adenoviruses can cause respiratory, gastrointestinal and ocular infections in humans. However, adenoviruses have attracted attention in recent years due to their potential use in gene therapy and vaccine development. Their ability to efficiently deliver genes into mammalian cells has made them valuable tools in medical research, and they’re being explored as potential treatments for certain genetic disorders. Theriva Biologics (NYSE American: TOVX) is a biotech company that is looking to use adenoviruses in its novel cancer treatment. Adenoviruses are a class of viruses with an established safety profile and are highly prevalent in the environment, making them ideal candidates for therapeutic use in the cancer field. Theriva Biologics' lead product candidate, VCN-01, is a uniquely modified human adenovirus type 5 that is designed for systemic delivery to treat different types of cancer. This systemic delivery approach means that it can target both the main tumor and the distant metastases, making it a promising therapeutic option for various advanced and difficult-to-treat cancers. One of the additional distinguishing features of the VCN-01 adenovirus is its ability to degrade the protective barrier around the tumor, referred to as the stroma or the matrix. To do this, it releases an enzyme called hyaluronidase, which is a unique feature not found in other viruses being developed as cancer therapies. The virus's high replication capacity allows more virus particles and more hyaluronidase to be produced in the tumor, thereby degrading the stroma and making the tumor more immunogenic and receptive to chemotherapy and immunotherapy. By killing tumor cells and breaking down the tumor protective barrier, the virus can also turn a cold tumor "hot" and further facilitate immune system activity. Theriva Biologics reports that phase 1 clinical trials of VCN-01 have shown promising results when administered alone or with chemotherapy or immunotherapy in several different indications, including pancreatic cancer, retinoblastoma, head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC). Theriva Biologics is currently advancing VCN-01 in a phase 2b clinical trial in combination with standard-of-care chemotherapy for first-line metastatic pancreatic cancer. The company says it is on track to complete enrollment of all participants in the VIRAGE Study by the first half of 2024, which would mark an important milestone in the candidate’s development. The company is considering an interim analysis of the data collected during the VIRAGE Study by the second half of 2024. This analysis will offer valuable insights into the effectiveness of VCN-01 and its potential as a treatment option for first-line metastatic pancreatic cancer. If the company can successfully harness the benefits of adenoviruses, it will present suffering patients around the globe with a novel solution to extend their lives. CG Oncology (NASDAQ: CGON), Calidi Biotherapeutics (AMEX: CLDI) and Candel Therapeutic s (NASDAQ: CADL) are companies also advancing different adenoviruses for cancer treatment. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

March 06, 2024 08:30 AM Eastern Standard Time

Image
Article thumbnail News Release

Roberts & Ryan Inc. Joins NYSE and Welcomes the Mark J. Muller Equities Team to Strengthen Its Equity Trading Operations.

Roberts & Ryan, Inc.

Roberts & Ryan Inc., a Veteran Owned broker-dealer, is delighted to announce it has been approved for membership by the New York Stock Exchange and began operating today on the iconic NYSE trading floor. In conjunction with this milestone, the firm proudly introduces the esteemed Mark J. Muller Equities trading team to its floor operation. Comprising seasoned professionals including Mark Muller and Robert Moran, the team brings a wealth of experience and expertise to Roberts & Ryan Inc. The addition of the Mark J. Muller Equities trading team to the firm's already robust equity trading platform serves to fortify Roberts & Ryan's capabilities, reinforcing the company's commitment to anticipating and addressing client needs and concerns. Membership at the NYSE will empower the firm to harness broader liquidity pools, achieve parity in situational trading, and access real-time insights from point-of-sale access. These synergies, combined with Roberts & Ryan's existing institutional trading operation, will enhance the company's ability to serve equity clients effectively. Additionally, Roberts & Ryan will be well-positioned to assist clients during key price discovery events on the NYSE Floor, such as IPOs and secondary offerings. Founded on the core value of prioritizing competence, Roberts & Ryan Inc. places client satisfaction at the forefront of its operations. As a Veteran-Owned firm with the requisite certifications to fulfill all DEI mandates and set-asides, the company is dedicated to its social mission. A portion of all commission dollars earned is donated to foundations supporting Veterans and other deserving charities. Since 2018, this initiative has generated over $1.8 million in charitable contributions, benefiting more than 800 Veterans and their families. The combination of competency, diversity, and charity has enabled Roberts & Ryan Inc. to make a meaningful impact in the community. When asked to share his thoughts, Mark Muller, Managing Director of Roberts & Ryan's NYSE Floor Operations, remarked, "The Muller team is excited to be part of the Roberts & Ryan family, a firm that not only provides great service to its clients, but also supports our nation's Veterans and disadvantaged young adults. With our shared vision and commitment to excellence, we will continue to provide value-added executions from the floor of the NYSE." "With these strategic developments, Roberts & Ryan Inc. is poised to deliver enhanced services and value to our clients while upholding our commitment to excellence, integrity, and social responsibility," said Edward D'Alessandro, Chief Executive Officer of Roberts & Ryan, Inc. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.8 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, focusing primarily on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Roberts & Ryan, Inc. Sadie Millard, Chief Administrative Officer +1 646-542-0012 smillard@roberts-ryan.com Company Website https://www.roberts-ryan.com

March 04, 2024 12:00 PM Eastern Standard Time

Image
Article thumbnail News Release

Centre for Neuro Skills Study Finds Differences in Sleep Patterns Between Men and Women with Post-Traumatic Brain Injury

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a premier provider of traumatic and acquired brain injury rehabilitation services, has shared findings from a study researching sleep-wake disturbances, published in Neurotrauma Reports on January 3, 2024. They found that sleep deficits are correlated with poorer brain injury patient outcomes (verbal skills, depression issues), as monitored by therapists and administrators at CNS. The study included data from 57 individuals between the ages of 18-70 who sustained traumatic brain injuries (TBIs). CNS collected the data between 2018-2020 at its in-house sleep centers in Dallas and Bakersfield. “Overall, we found that lack of REM sleep negatively impacts memory and learning for TBI patients,” says Dr. Stefanie Howell, a neuroscientist at CNS. “In research, we must also consider additional variables that may impact our results. This includes biological variables such as sex, as biological sex does impact sleep. Our research found that women achieve REM sleep far less than men. Additionally, a decrease in REM sleep was associated with poorer learning and memory task performance, indicating a potential impact on outcome and recovery.” In addition to biological sex, CNS evaluated several sleep medications to determine if their use impacted sleep for TBI patients. Howell said “medications do not seem to be impacting results between men and women; however, the use of melatonin was associated with improved REM sleep and may therefore be of potential short-term benefit to TBI patients. It is important to note that over-the-counter melatonin options are variable due to formula ingredients.” “Through research, we’ve found that while sleep supplements in the benzodiazepine family may cause someone to fall asleep, they suppress REM sleep, which is crucial for memory recollection and improved learning,” says Dr. Brent Masel, executive vice president of medical affairs at CNS. “Melatonin was found to help improve REM sleep in the short term, but it’s important to note that long-term use can be habit-forming. I cannot stress this enough – the best medication is no medication.” In 2021, CNS published two other studies regarding sleep-wake disturbances post-stroke. The first evaluated the incidence of obstructive sleep apnea (OSA) and the second study considered the anatomical location of the injury (stroke). *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

March 04, 2024 08:01 AM Pacific Standard Time

Image
Article thumbnail News Release

MicroSalt revolutionises salt intake with low sodium technology and big growth plans

MicroSalt PLC

MicroSalt PLC (AIM: SALT) CEO Rick Guiney tells Proactive's Stephen Gunnion that the recently listed company specialises in innovative food technology that enhances the flavour of salt with significantly less sodium through patented technology. This technology changes the salt crystal's size, increasing its surface area for a fuller flavour without excess sodium intake, a major global health concern. The company targets food manufacturers, offering a product with the same functionality as traditional salt but processed differently. Additionally, MicroSalt aims to enter consumer markets, with products already available on Amazon in the UK and in about 500 stores in the US. MicroSalt's technology is distinguished by an exclusive patent, marking a significant advancement in efforts to reduce sodium consumption over the past two decades. The company's strategy includes expanding into the UK retail market, engaging with major supermarket groups to offer MicroSalt on shelves and incorporate it into their own brands, aiming for products like crisps to retain their taste while having 50% less sodium. The decision to list on the AIM market reflects London's receptivity to small food technology firms and its strategic importance in the food and ingredients sector. MicroSalt's IPO aims to raise public awareness about its low-sodium solution and the broader health issues related to sodium intake. Regulatory support for low sodium initiatives is significant, with governments recognizing the health and economic benefits of reducing sodium consumption. MicroSalt has also announced an export collaboration with American Trading International (ATI), facilitating access to 90 markets through ATI's distribution network, and enhancing the company's growth prospects. Looking ahead, MicroSalt anticipates significant developments in 2024 and 2025 as it expands its reach to consumers and large food manufacturers. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

March 04, 2024 08:47 AM Eastern Standard Time

Video
1 ... 2627282930 ... 273